EGFR Exon 20–Altered NSCLC: A Personalized Approach to Improve Patient Outcomes

Join us for this dynamic, live, CME-certified webinar where experts will provide their insights on the emerging role of EGFR exon 20 insertion mutations in the management of advanced NSCLC via a series of patient cases, including a discussion on the latest clinical data. This webinar will offer attendees the opportunity to have their questions answered by an expert panel.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the event.


Welcome and Introduction
Assessing EGFR Mutation and MET Amplifications Status in NSCLC
Therapeutic Planning in NSCLC Harboring Exon 20 Insertion Mutations
Putting It All Together: Tumor Board–Style Case Discussions by Faculty Panel
Final Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Enriqueta Felip, MD

Head,Thoracic Oncology Unit
Oncology Service
Vall d'Hebron University Hospital
Barcelona, Spain

Alexander Spira, MD

Medical Oncologist
Assistant Professor of Oncology
Johns Hopkins School of Medicine
Baltimore, MD, USA

Goal Statement
The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to plan individualized treatment for patients with EGFR Mut+ NSCLC.

Target Audience
This program is intended for oncologists, pathologists, pulmonologists, and other healthcare providers who care for patients with NSCLC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement best practices and guideline-endorsed molecular testing algorithms in NSCLC, including the use of tissue-based and blood-based biomarker testing for evaluation of EGFR exon 20 mutation status
  • Describe the medical need for new therapies for patients with NSCLC harboring EGFR exon 20 insertion mutations or MET amplifications
  • Appraise the available and emerging clinical trial data on EGFR-MET bispecific antibody and next-generation EGFR TKI therapies in the management of patients with advanced NSCLC with EGFR exon 20 insertion mutations
  • Identify patients eligible to enroll on important ongoing clinical trials evaluating promising investigational agents and combinations for NSCLC with EGFR exon 20 mutations


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.